ENN 104
Alternative Names: ENN-104Latest Information Update: 22 Sep 2022
At a glance
- Originator EnnovaBio
- Class Anti-inflammatories
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - Inflammation
Highest Development Phases
- Research Inflammation; Unspecified
Most Recent Events
- 22 Sep 2022 Early research in Unspecified in China (unspecified route) (EnnovaBio pipeline, September 2022)
- 12 Sep 2022 ENN 104 is available for licensing as of 12 Sep 2022. http://www.ennovabio.com/en/xmhz.html
- 12 Sep 2022 Early research in Inflammation in China (unspecified route) (EnnovaBio pipeline, September 2022)